BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B. Takeda Ventures Inc. led the financing with...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Extra | Dec 18, 2019
Company News

Ipsen’s Meek to helm Ferring’s gene therapy unit

David Meek will step down as CEO of Ipsen at year end to become president and CEO of Ferring’s newly formed gene therapy subsidiary, effective Jan. 14. Ferring Pharmaceuticals A/S and Blackstone Life Sciences launched...
BC Extra | Dec 6, 2019
Company News

FDA hold muddies Ipsen’s timeline for palovarotene in rare bone disease

A partial clinical hold on four studies of palovarotene that shaved $1.1 billion from Ipsen’s market cap on Friday could slow the biopharma’s timeline for a planned NDA to treat rare bone disease fibrodysplasia ossificans...
BC Extra | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013...
BC Extra | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
Items per page:
1 - 10 of 920
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B. Takeda Ventures Inc. led the financing with...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Extra | Dec 18, 2019
Company News

Ipsen’s Meek to helm Ferring’s gene therapy unit

David Meek will step down as CEO of Ipsen at year end to become president and CEO of Ferring’s newly formed gene therapy subsidiary, effective Jan. 14. Ferring Pharmaceuticals A/S and Blackstone Life Sciences launched...
BC Extra | Dec 6, 2019
Company News

FDA hold muddies Ipsen’s timeline for palovarotene in rare bone disease

A partial clinical hold on four studies of palovarotene that shaved $1.1 billion from Ipsen’s market cap on Friday could slow the biopharma’s timeline for a planned NDA to treat rare bone disease fibrodysplasia ossificans...
BC Extra | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013...
BC Extra | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
Items per page:
1 - 10 of 920